Tags

Type your tag names separated by a space and hit enter

Alternative and complementary therapies for the menopause.
Menopause Int. 2012 Mar; 18(1):20-7.MI

Abstract

Despite a re-evaluation of risks in recent years, hormone replacement therapy is still surrounded by controversy. Almost 30% of women in a recent survey sought a natural approach to combat climacteric symptoms. Nevertheless, a large proportion of patients felt that they wanted a good safety profile and strong evidence base for treatment. This article seeks to review the evidence supporting non-hormonal approaches to treatment. There is only conflicting evidence at best to support alpha-2 agonists, e.g. clonidine and limited evidence for dihydroepiandrosterone and natural progesterones. There is limited randomized controlled trial data for gabapentin, selective norepinephrine re-uptake inhibitors (SNRIs) and selective serotonin re-uptake inhibitors (SSRIs), many of these studies being related to breast cancer patients. Of the herbal medicinal products, the largest evidence base rests with phytoestrogens. A Cochrane Database review looking at all types of phytoestrogens, e.g. red clover extracts, dietary soya and soya extracts concluded that there was no evidence to support improvement in climacteric symptoms and the meta-analysis of a 178 studies on soy products was inconsistent. Nevertheless, other studies disagree. Mammographic density is not affected by soy or phytoestrogen products and recent in vitro work shows only a weakly proliferative effect of soy isoflavone on breast cancer cells and evidence that soy isoflavone blocks the proliferative effect of estradiol on these cells. There are no studies looking at clinical outcome measures for cardiovascular disease but a number of studies looking at biochemical markers including arterial wall stiffness and apolipo protein B. Recent studies have also looked at the effects of red clover isoflavone on mood and depression, using specific depression rating scales. Finally, it is important to note that herbal medicinal products should not be used without caution. Some may produce quite marked side-effects in high doses and others can interact with pre-existing medication. A strategy for which patients are suitable for herbal medicinal products is reviewed.

Authors+Show Affiliations

Northwick Park & St Marks Hospital (NPMH), NW London Hospitals NHS Trust, Watford Road, Harrow, HA1 3UJ, UK, joan.pitkin@nwlh.nhs.uk

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22393177

Citation

Pitkin, Joan. "Alternative and Complementary Therapies for the Menopause." Menopause International, vol. 18, no. 1, 2012, pp. 20-7.
Pitkin J. Alternative and complementary therapies for the menopause. Menopause Int. 2012;18(1):20-7.
Pitkin, J. (2012). Alternative and complementary therapies for the menopause. Menopause International, 18(1), 20-7. https://doi.org/10.1258/mi.2012.012001
Pitkin J. Alternative and Complementary Therapies for the Menopause. Menopause Int. 2012;18(1):20-7. PubMed PMID: 22393177.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alternative and complementary therapies for the menopause. A1 - Pitkin,Joan, PY - 2012/3/7/entrez PY - 2012/3/7/pubmed PY - 2012/6/23/medline SP - 20 EP - 7 JF - Menopause international JO - Menopause Int VL - 18 IS - 1 N2 - Despite a re-evaluation of risks in recent years, hormone replacement therapy is still surrounded by controversy. Almost 30% of women in a recent survey sought a natural approach to combat climacteric symptoms. Nevertheless, a large proportion of patients felt that they wanted a good safety profile and strong evidence base for treatment. This article seeks to review the evidence supporting non-hormonal approaches to treatment. There is only conflicting evidence at best to support alpha-2 agonists, e.g. clonidine and limited evidence for dihydroepiandrosterone and natural progesterones. There is limited randomized controlled trial data for gabapentin, selective norepinephrine re-uptake inhibitors (SNRIs) and selective serotonin re-uptake inhibitors (SSRIs), many of these studies being related to breast cancer patients. Of the herbal medicinal products, the largest evidence base rests with phytoestrogens. A Cochrane Database review looking at all types of phytoestrogens, e.g. red clover extracts, dietary soya and soya extracts concluded that there was no evidence to support improvement in climacteric symptoms and the meta-analysis of a 178 studies on soy products was inconsistent. Nevertheless, other studies disagree. Mammographic density is not affected by soy or phytoestrogen products and recent in vitro work shows only a weakly proliferative effect of soy isoflavone on breast cancer cells and evidence that soy isoflavone blocks the proliferative effect of estradiol on these cells. There are no studies looking at clinical outcome measures for cardiovascular disease but a number of studies looking at biochemical markers including arterial wall stiffness and apolipo protein B. Recent studies have also looked at the effects of red clover isoflavone on mood and depression, using specific depression rating scales. Finally, it is important to note that herbal medicinal products should not be used without caution. Some may produce quite marked side-effects in high doses and others can interact with pre-existing medication. A strategy for which patients are suitable for herbal medicinal products is reviewed. SN - 1754-0461 UR - https://www.unboundmedicine.com/medline/citation/22393177/Alternative_and_complementary_therapies_for_the_menopause_ L2 - https://medlineplus.gov/herbalmedicine.html DB - PRIME DP - Unbound Medicine ER -